Tenax Therapeutics Amends Executive Severance Terms for Three Leaders
TENX has more than doubled off its 52-week low of $5.66.
Summary
Tenax Therapeutics has amended the employment agreements for three key executives, Christopher Giordano, Stuart Rich, and Thomas Staab, effective June 26, 2026. These updates provide specified severance and change-in-control benefits, including accelerated equity vesting for Stuart Rich in the event of a change-in-control termination. This follows an 8-K filed earlier today disclosing these changes. While a standard corporate governance move, these amendments formalize potential liabilities for the company in future executive transitions or M&A scenarios.
At the time of this announcement, TENX was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $358.1M. The 52-week trading range was $5.66 to $18.38. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.